Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase EARLY_PHASE1 1Phase 2 1Phase 1/2 1Phase 1 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Renal Insufficiency 1Kidney Failure, Chronic 1Carcinoma, Renal Cell 1

Interventions

Cyclophosphamide 250Radiotherapy 172pembrolizumab 154Carboplatin 146Gemcitabine 139Nivolumab 135Paclitaxel 129Dexamethasone 118Cisplatin 118fludarabine 115Rituximab 104Lenalidomide 103Bevacizumab 99Docetaxel 97Capecitabine 97fludarabine phosphate 92Temozolomide 89Cytarabine 89Oxaliplatin 87Etoposide 82Filgrastim 77Irinotecan 73Doxorubicin 73venetoclax 70Peripheral Blood Stem Cell Transplantation 68Fluorouracil 68Radiosurgery 66Melphalan 66Everolimus 66Bortezomib 66

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × OTHER × Kidney Transplantation × Clear all
NCT07053462 2025-07-08

CRISPR-Edited HLA Donor Kidney Transplant to Reduce Rejection Risk

AMERICAN ORGAN TRANSPLANT AND CANCER RESEARCH INSTITUTE LLC

Phase 1/2 Recruiting
90 enrolled
Genitourinary

Carcinoma, Renal Cell, Kidney Failure, Chronic, Renal Insufficiency

Data powered by HemOnc (CC BY 4.0) Colophon âš¡